184 results for "Microdosing"
Health-related behavioral changes following the use of psychedelics in naturalistic settings.
Preventive medicine reports – August 01, 2025
Summary
No Summary
Abstract
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader heal...
Dosing Psychedelics and MDMA.
Current topics in behavioral neurosciences – January 01, 2022
Summary
No Summary
Abstract
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, espec...
Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis
Drug Testing and Analysis – October 29, 2020
Summary
Dried mushroom biomass stored in the dark at room temperature best preserves its psychoactive compounds. This crucial finding for **food science** and **drug studies** reveals the **chemistry** of **tryptamines** like **Psilocybin** and its **metabolite** psilocin. While **mycelium** contained 0.47 wt.% psilocin, **mushroom** caps boasted 1.03 wt.% **tryptamine** **alkaloids**, double the stipes (0.52 wt.%). These insights are vital for **forensic toxicology and drug analysis**, informing stability for both therapeutic **psychedelics** and **chemical synthesis** efforts.
Abstract
Abstract Psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin are tryptamines structurally similar to the neurotransmitter serotonin. ...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Treatment of neuropathic pain with repeated low-dose MDMA: a case report.
Frontiers in psychiatry – January 01, 2025
Summary
A groundbreaking case shows how MDMA microdosing provided lasting relief for severe chronic pain. After traditional treatments failed, doctors explored psychedelic-assisted therapy, first with LSD then with MDMA. Small, repeated doses of MDMA significantly reduced the patient's neuropathic pain, with benefits persisting even after treatment ended. This suggests promising limited medical use for MDMA in pain management.
Abstract
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium...
The Evolution of Do-It-Yourself Brain Hacking: From Fringe to Frontier.
Cureus – June 01, 2025
Summary
Remarkably, self-directed brain hacking, once niche, now influences mainstream healthcare. This biohacking evolution, driven by a desire for cognitive optimization, saw early users explore nootropics, microdosing, and transcranial stimulation. Such personal neuroenhancement efforts, leveraging neurotechnology, have inspired regulated digital therapeutics. As programmable cognition becomes a reality, medical stewardship is vital for safe and effective advancements.
Abstract
Do-it-yourself (DIY) brain hacking has evolved from fringe experimentation to a cultural and clinical phenomenon reshaping how individuals interact...
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
Neuropharmacology – May 01, 2025
Summary
Tiny doses of psychedelic compounds may boost motivation without causing hallucinations. Scientists found that mice given ultra-low doses of 2,5-dimethoxy-4-propylamphetamine showed increased drive to work for rewards, but only in previously unmotivated animals. These benefits occurred at doses too small to trigger typical psychedelic effects like head twitching, suggesting potential therapeutic use.
Abstract
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeu...
The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK.
Frontiers in psychology – January 01, 2024
Summary
During COVID-19 lockdowns, UK universities saw a striking 42% increase in students using cognitive enhancement drugs like Modafinil. A survey of 736 students and staff revealed significant upticks in psychoactive drug use, including microdosing psychedelics, as people adapted to remote learning. Lower agreeableness and conscientiousness emerged as key personality factors predicting drug use.
Abstract
The use of psychoactive substances to increase cognitive performance while studying has been termed 'pharmacological cognitive enhancement' (PCE). ...
Inter-individual variability in neural response to low doses of LSD.
Translational psychiatry – July 15, 2024
Summary
Small doses of LSD affect people differently based on their baseline mental state. In a groundbreaking study, participants receiving micro-amounts of LSD showed increased alertness and attention, with effects strongest in those who initially had lower cognitive performance. Brain activity changes persisted for a week after treatment, suggesting lasting neural adaptations.
Abstract
The repeated use of small doses of psychedelics (also referred to as "microdosing") to facilitate benefits in mental health, cognition, and mood is...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Journal of Psychoactive Drugs – August 31, 2023
Summary
Remarkably, a man with microsmia regained his sense of smell after taking 6g of psilocybin mushrooms. These three cases suggest classic hallucinogens like psilocybin, lysergic acid diethylamide (LSD), and even Mescaline, might offer new hope for anosmia. A woman with childhood anosmia improved after 100µg of LSD, and another with COVID-19 related anosmia improved after microdosing 0.1g of psilocybin. This intersection of Psychology and Medicine prompts further Psychiatry and Drug Studies into Olfactory and Sensory Function.
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is...
Psilocybin’s effects on cognition and creativity: A scoping review
Journal of Psychopharmacology – July 01, 2023
Summary
Psilocybin, a potent hallucinogen, reveals complex effects on human cognition and creativity, a significant focus in clinical psychology. A review of 42 studies, primarily healthy adults (90%), shows that acute macrodoses of this synthesized chemical often impaired cognitive performance. However, microdoses tended to enhance creativity. The neurotransmitter receptor influence on behavior appears time-dependent; while initial impairment was observed, some positive effects emerged days later, hinting at developmental psychology implications from these psychedelic drug studies.
Abstract
Background: Research on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psil...
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Tiny amounts of LSD can boost the brain's reward processing systems, even without causing noticeable psychedelic effects. Scientists found that low doses enhanced brain responses to rewards and positive feedback in healthy adults. Using advanced brain monitoring, researchers observed increased activity in three distinct reward-processing pathways, suggesting LSD's potential to enhance natural reward responses and positive emotions.
Abstract
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single...
LSD Restores Synaptic Plasticity in VTA of Morphine-Treated Mice and Disrupts Morphine-Conditioned Place Preference.
bioRxiv : the preprint server for biology – June 15, 2025
Summary
Could psychedelics unlock new addiction treatments? One study shows LSD can reverse brain changes caused by opioids. In mice, a single dose or microdoses of LSD quickly reduced morphine preference. It also restored vital brain cell connections, previously damaged by morphine, and induced beneficial epigenetic shifts. These findings suggest LSD can positively reshape reward circuits, attenuating drug-seeking behaviors.
Abstract
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potenti...
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Translational Psychiatry – August 11, 2022
Summary
A single high dose of the hallucinogen psilocybin reduced sucrose preference in mice, hinting at its influence on reward pathways. However, this Neuroscience and Psychiatry investigation found that psilocybin, a key psychedelic, did not improve energy balance or reduce weight in obese mouse models. Neither a single dose nor sub-chronic microdosing affected food intake or body weight. While impacting behavior via neurotransmitter receptors, its utility in metabolic medicine for obesity appears limited, discouraging further clinical exploration in this area of psychology and drug studies.
Abstract
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psiloc...
Advances in Psychedelic Medicine
OpenAlex – January 01, 2019
Summary
Psychedelics are rapidly transforming Medicine, with the U.S. government lifting its testing ban over a decade ago. Substances like Psilocybin, MDMA, and the hallucinogen Ayahuasca are now being integrated into Psychiatry and Psychology, augmenting psychotherapies for conditions like Addiction and depressive disorders. This comprehensive assessment covers clinical efficacy, safety, and ethical considerations, alongside neuroscience findings. It also explores microdosing, cannabinoid research, and training future psychotherapists in this evolving field of Psychedelics and Drug Studies.
Abstract
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psycho...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
Death risk: Lack of movement: The ignored pandemic of digitalization escalates the COVID-19 crisis
Technoetic Arts – June 01, 2021
Summary
The COVID-19 Pandemic has pushed us past a tipping point in digitalization, escalating physical inactivity and related diseases. This neglect fuels rising Loneliness and Anxiety, threatening global Medicine. Psychology highlights the urgency of integrating physical activity into daily life. Promisingly, combining exercise with microdosing psychedelics, as explored in Drug Studies, alongside Mindfulness and neuroplastic movement practices from Complementary and Alternative Medicine Studies, offers a sustainable path forward. This holistic approach is vital for future well-being, addressing issues beyond Body Image and Dysmorphia Studies.
Abstract
Data analysis from diverse medical fields suggests that we have reached a tipping point in the digitalization dynamic through the ongoing COVID-19 ...
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.
Neuroscience and biobehavioral reviews – June 01, 2025
Summary
Psilocybin-assisted psychotherapy shows remarkable promise in addiction treatment, with some studies reporting up to 80% success in helping people overcome substance use disorders. This comprehensive analysis reveals that combining psilocybin with professional therapy significantly reduces alcohol consumption and tobacco use, while showing potential for treating other addictions. The treatment appears safe and effective.
Abstract
Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remai...
Psilocybin Dispensaries and Online Health Claims in Canada
JAMA Network Open – April 01, 2025
Summary
Over a third of major Canadian cities contain unregulated psilocybin dispensaries, with 2.6% of Canadians living near one. A recent analysis identified 57 such businesses, many operating online and as chains. While 86.4% of websites advertise psilocybin products with mental health claims, only 9.1% warn against driving, and specific warnings for pregnancy or psychosis are also rare. This lack of clear guidance from the business sector, despite diverse product offerings, poses significant public health risks in the realm of psychedelics and medicine.
Abstract
Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there hav...
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.
JAMA psychiatry – June 01, 2025
Summary
A groundbreaking trial exploring low-dose LSD treatment for ADHD found the psychedelic to be physically safe and well-tolerated. Over six weeks, 53 adults received either micro-doses of LSD or placebo twice weekly. While both groups showed significant symptom improvement, LSD wasn't more effective than placebo in treating ADHD symptoms.
Abstract
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disord...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
Philosophical Transactions of the Royal Society B Biological Sciences – October 21, 2024
Summary
Individuals receiving psilocybin-assisted neurofeedback reported significant self-reported improvements in daily executive functions, crucial for mental health and physical medicine and rehabilitation. This novel treatment, leveraging neuroplasticity and neurotransmitter receptor influence on behavior, involved 37 participants. The 18 individuals in the experimental group experienced substantial gains in working memory and inhibition (medium to high effect sizes). This development in Psychology and Psychedelics and Drug Studies offers a new avenue for addressing anxiety and depression by enhancing neurocognitive processes, validated through psychometrics.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Psychedelics and schizophrenia: a double-edged sword.
Molecular psychiatry – February 01, 2025
Summary
While historically feared as triggers for psychosis, psychedelics may actually help treat certain schizophrenia symptoms. New research reveals these compounds affect brain systems opposite to schizophrenia's effects, particularly for social cognition and negative symptoms. Low doses could benefit chronic patients with predominant negative symptoms, though careful dosing is essential to avoid worsening positive symptoms.
Abstract
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experim...
A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
International Journal of Molecular Sciences – August 07, 2023
Summary
A compelling finding suggests psychedelics could significantly alleviate the burden of Alzheimer's disease, a prevalent dementia affecting our aging population. These drug studies indicate their unique mechanism of action, primarily as serotonin receptor agonists, may offer crucial psychiatric benefits. By modulating pathways linked to tryptophan and brain disorders, this medicine could attenuate depressive symptoms often associated with the disease. Reviews of preclinical and clinical findings highlight the potential for novel treatments via chemical synthesis, targeting the disease's psychological pathology.
Abstract
Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the populat...
Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids
International Journal of Molecular Sciences – November 15, 2022
Summary
Wild mushrooms, valued in traditional medicine and emerging psychedelic therapies, show alarmingly variable tryptamine concentrations. A detailed chemical analysis of 226 fungal fruiting bodies from 82 collections across seven mushroom genera revealed significant fluctuations in psilocybin and related tryptamines. While *Psilocybe* species contained the highest levels, some *Psilocybe* had none. This variability in fungal biology poses overdose risks for consumers and complicates drug studies, as the precise chemistry of these natural alkaloids differs vastly from chemically pure psilocybin, impacting potential therapeutic applications.
Abstract
Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their c...
An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
Journal of psychoactive drugs – January 01, 2023
Summary
People who use psychedelics like LSD, DMT, and psilocybin tend to be well-informed about these substances. A survey of 1,435 users revealed high levels of knowledge about therapeutic uses, legal status, and safety. Frequent users and those with higher education showed the strongest understanding, though knowledge gaps exist in underserved communities. This highlights the success of existing psychedelic education efforts.
Abstract
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use ...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...
"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.
Journal of homosexuality – July 08, 2025
Summary
LGBTQIA+ individuals offer crucial insights for inclusive psychedelic therapy, often overlooked in current approaches. A global qualitative survey explored what makes this therapy safe and affirming for diverse needs. Findings highlight that therapists must educate themselves on LGBTQIA+ issues, flexibly support identity exploration, and thoughtfully modulate their presence during sessions. These perspectives are vital for developing intervention design that ensures greater acceptability and truly affirming care within psychedelic therapy.
Abstract
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ indivi...
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Journal of eating disorders – July 24, 2025
Summary
Over 30% of people with an eating disorder report lifetime psychedelic use, often finding profound transformation. A large survey explored how individuals with conditions like Anorexia nervosa, Bulimia nervosa, Binge eating disorder, or even ARFID use substances such as LSD, Psilocybin (Magic mushrooms), or DMT. Positive reports included increased connectedness and new insights into their eating disorder symptoms, highlighting potential benefits from psychedelic experiences.
Abstract
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating...
Ibogaine therapy for addiction: Consumer views from online fora.
The International journal on drug policy – September 01, 2020
Summary
Individuals exploring ibogaine therapy for addiction often find vital support and information within online fora. Analyzing discussions from popular online communities like Reddit revealed that these platforms are key resources for understanding ibogaine's use and risks. Users value personal experiences and evidence-based information, discussing treatment safety and harm reduction extensively. Positive psychological changes from the psychedelic experience were frequently reported. These online spaces foster a sense of community, where neuroscientific explanations of addiction resonate, providing a valuable platform for peer support related to ibogaine treatment.
Abstract
Background Ibogaine is a psychedelic drug used by for-profit clinics and lay-people to treat addiction, despite some reported fatalities and a lack...
Cardiovascular effects and safety of classic psychedelics.
Nature cardiovascular research – February 01, 2025
Summary
No Summary
Abstract
Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including de...
The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal – January 05, 2023
Summary
Psilocybin, a potent hallucinogen, shows strong therapeutic potential for alcohol use disorder. Psilocybin-assisted psychotherapy offers a promising new tool for psychotherapists and psychiatry within clinical psychology and medicine. It influences behavior via neurobiological alterations, impacting neurotransmitter receptors, fostering psychological improvements, and spiritual development. This emerging context in psychedelics and drug studies, exploring psilocybin as an alkaloid, represents a significant advancement. Its efficacy suggests a valuable addition to addiction treatment.
Abstract
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric communit...
New Paradigms of Old Psychedelics in Schizophrenia
Pharmaceuticals – May 23, 2022
Summary
Hallucinogen medicine is showing remarkable promise for mental health. Recent Psychedelics and Drug Studies reveal that compounds like Psilocybin and Lysergic acid diethylamide are well-tolerated and effective for conditions such as severe Anxiety. Neuroscience indicates these substances, including Mescaline, primarily activate the Serotonin 5-HT2A receptor, influencing brain connectivity. This Serotonergic action suggests a "brain resetting" mechanism, offering new avenues in Psychology for treating complex disorders like Schizophrenia, by understanding these chemical synthesis and alkaloids' neurotransmitter receptor influence on behavior.
Abstract
Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and b...
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
Experimental and Clinical Psychopharmacology – January 10, 2019
Summary
Repeated dosing with the hallucinogen LSD significantly reduced depression-like effects in rats, offering a promising avenue for medicine. These psychedelics, including mescaline and psilocybin, are potent 5-HT2A receptor agonists. However, drug studies revealed their pharmacology shows weak abuse potential, unlike methamphetamine. This research highlights complex neurotransmitter receptor influence on behavior, a field explored in psychology, distinct from studies on, for example, nicotinic acetylcholine receptors.
Abstract
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enf...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
OpenAlex – October 11, 2023
Summary
Daily executive functions significantly improved for individuals undergoing psilocybin-assisted neurofeedback. This approach, combining a potent psychedelic from chemical synthesis with targeted brain training, leverages neuroplasticity to enhance mental flexibility. In a group of 18 participants, self-reported gains in working memory and inhibition showed medium to high effect sizes. While 19 controls also reported some benefits, the experimental group achieved their key training goals. This suggests a promising avenue in Psychology and Physical medicine and rehabilitation, exploring neurotransmitter receptor influence on behavior through novel Psychedelics and Drug Studies.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
OpenAlex – October 07, 2024
Summary
Psilocybin shows significant promise in mental health, driving a surge in psychedelics and drug studies. To understand this impact, a new protocol outlines a scoping review of existing qualitative research on psilocybin-assisted psychotherapy. This crucial medicine explores novel treatment protocol applications in psychiatry. Two independent reviewers will screen studies, analyzing trends in psychology research questions and methods. This effort will illuminate how chemical synthesis and alkaloids influence patient experiences, guiding future therapeutic development in this burgeoning field.
Abstract
IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may b...
Repeated low doses of psilocybin reduces perceived symptom severity of obsessive-compulsive disorder, but fails to restore cognitive flexibility: A case study of identical twins
OpenAlex – December 30, 2024
Summary
Low-dose psilocybin shows promise for Obsessive compulsive disorder symptoms, even without psychedelic effects. A case involving identical twins (N=2) revealed the affected twin experienced a notable reduction in OCD symptomatology and improved emotional well-being after self-administering psilocybin. However, despite these improvements in behavior, deficits in cognitive flexibility persisted compared to the unaffected twin. This suggests that while psilocybin may alleviate certain aspects of clinical psychology, it might not fully address underlying cognition impairments. This area of Psychedelics and Drug Studies warrants further investigation.
Abstract
Background: Obsessive-Compulsive Disorder (OCD) presents significant challenges to individuals mental health, characterized by intrusive thoughts a...
From Mushrooms to Myolysis
The Journal of Nervous and Mental Disease – July 29, 2022
Summary
No Summary
Abstract
Abstract The involvement of certain recreational drugs, namely, hallucinogens, in the development of hyperactive syndromes is well known, but not w...
Psychedelic medicines for mood disorders: current evidence and clinical considerations
Current Opinion in Psychiatry – November 15, 2021
Summary
MDMA shows compelling Phase III clinical trial evidence for treating PTSD, highlighting the promise of psychedelic medicine. Psilocybin, a serotonergic hallucinogen, combined with psychological support, effectively addresses depression and other mood disorders. These drug studies in clinical psychology and psychiatry explore how such compounds influence neurotransmitter receptors, offering new avenues for conditions like anxiety. While promising, current medicine often involves small sample sizes.
Abstract
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. ...
Mush Room for Improving Therapeutic Approaches in Psychiatry
Clinical Pharmacology & Therapeutics – March 15, 2023
Summary
Psilocybin, once a taboo "magic mushroom," is now a serious focus in medicine, moving beyond fictional drama's outrage. A recent extensive phase II clinical trial for treatment-resistant major depressive disorder yielded "intriguing and sobering" results, prompting a phase III study. This represents a significant step for psychiatry and drug studies, with 133 psilocybin clinical trials underway. Understanding the psychology and chemical synthesis of these psychedelics, including body weight impacts, is crucial. Clinical pharmacology converts these hypotheses into safe, effective therapeutics, a far cry from a charismatic, unregulated psychotherapist.
Abstract
In the televised fictional drama "Nine Perfect Strangers," based on a novel with the same name,1 nine people gather for a retreat in a wellness res...
Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
Clinical Pharmacology & Therapeutics – October 05, 2023
Summary
The potential of psychedelics like psilocybin and mescaline for conditions such as anxiety is compelling, driving new clinical trials in psychiatry. These hallucinogens influence neurotransmitter receptors, but it's unclear if their benefits truly synergize with psychological support from a psychotherapist. Rigorous 2x2 factorial clinical trials are crucial. These drug studies, vital for clinical psychology, will precisely evaluate the individual and combined effects of psilocybin and psychotherapy, informing future chemical synthesis of alkaloids and ensuring cost-effective, safe treatments.
Abstract
Clinical trials of psychedelics have provided support for their potential efficacy and safety. Although most combined a psychedelic with psychologi...
Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
British Journal of Clinical Pharmacology – July 17, 2023
Summary
A compelling 95% probability of success was observed for medical cannabis in treating childhood epilepsy, with all 20 patients improving. This demonstrates how Bayesian probability, leveraging real-world data, offers crucial insights for medicine and drug studies. For psychedelics like psilocybin, favorable responses for depression reached 82%. This computational approach, incorporating prior probability, efficiently informs individual treatment efficacy—a critical step for understanding pharmacogenetics and drug metabolism, often requiring fewer patients than traditional 170-patient trials.
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A ...
Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders
OpenAlex – May 02, 2024
Summary
Remarkably, psilocybin, a naturally occurring alkaloid, shows significant promise in psychiatry for treating Alcohol use disorder and other substance use issues. Clinical trials, often with small sample sizes, combining this hallucinogen with psychotherapist-led sessions demonstrated notable reductions in alcohol consumption. Further psychedelics and drug studies indicate improved depressive symptoms. Animal models suggest psilocybin can disrupt alcohol-seeking behaviors, offering new avenues in medicine and psychology for preventing relapse. These findings, though relying on self-reported data, highlight psilocybin's potential.
Abstract
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current ...
476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Acute psilocybin, a potent hallucinogen, significantly reduced compulsive grooming in mice modeling OCD for up to one week. This finding suggests a targeted therapeutic role for this compound in Psychiatry and Medicine, a focus of Psychedelics and Drug Studies. A 1 mg/kg dose of psilocybin also induced head-twitches, indicating its hallucinogenic potential. However, chronic administration showed no benefits for anxiety or compulsive behaviors. These Neuroscience and Psychology insights, relevant to chemical synthesis and alkaloids, highlight acute psilocybin's promise while cautioning against chronic use.
Abstract
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the n...
Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review
Clinical Neuropharmacology – September 01, 2025
Summary
A compelling finding emerges from **Psychedelics and Drug Studies** exploring psilocybin for autism spectrum disorder (ASD). Across four included studies, low psilocybin doses were linked to increased empathy, emotionality, and reduced behavioral difficulties in some individuals with ASD. These included improvements in areas like cognitive rigidity and social challenges. Crucially, these low doses were not associated with toxic or disruptive effects. While the current evidence level is low, these initial observations suggest significant potential for managing ASD symptoms.
Abstract
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the availab...
EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
A compelling neuroscience finding reveals psilocybin, a potent hallucinogen, significantly alleviates neuropathic pain. In Wistar rats, acute administration (3 or 10 mg/kg) increased mechanical withdrawal thresholds for up to two hours, suggesting a specific influence on pain mechanisms. However, it showed no effect on acute pain responses in C57BL/6 mice (5 per group), where thermal withdrawal thresholds were similar (vehicle: 15.6°C; psilocybin: 17.28°C). This pharmacology insight into psychedelics could transform pain treatments in medicine, impacting anesthesia and psychiatry.
Abstract
Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exo...
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Journal of Psychedelic Studies – September 01, 2019
Summary
Psychedelics, a focus of modern Drug Studies, offer profound benefits beyond treatment, enhancing well-being in healthy individuals. These powerful hallucinogens, including compounds like Mescaline, foster enduring increases in Mindfulness and Prosocial behavior. Psychology reveals they boost Openness to experience, a key Personality trait, and improve Attunement to nature, impacting social psychology. Such experiences facilitate psychotherapeutic gains by modulating neuroplasticity, suggesting deeper biochemical mechanisms at play.
Abstract
We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of menta...
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Frontiers in Neuroscience – March 15, 2022
Summary
Psychedelics offer profound potential to revolutionize psychiatry, showing promise for treating anxiety and addiction. Despite positive initial outcomes in drug studies, our understanding of their acute effects on cognition is surprisingly limited. Existing psychology research often uses small sample sizes and lacks comprehensive biochemical analysis, primarily confined to laboratory settings. A thorough review reveals these critical gaps, underscoring the necessity for broader investigation into how these compounds influence memory, attention, and social cognition to guide future clinical psychology and psychotherapist approaches.
Abstract
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe
Emerging Trends in Drugs Addictions and Health – December 01, 2025
Summary
The red fly agaric has surged in popularity over the past decade, leading to a concerning rise in hospitalizations and fatalities. Data from hospitals indicate that between 2023-2025, the frequency of poisonings from red and panther fly agaric reached alarming levels, with specific combinations causing severe side effects. Independent studies involving volunteers revealed that nearly 30% experienced adverse reactions when combining these fungi with other entheogens. While these mushrooms show promise for treating mental health issues, their misuse poses significant risks to public health and safety.
Abstract
The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to ...
The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Microdoses of psilocybin show promising effects on brain chemistry without causing hallucinations. When given to rats, small amounts triggered positive neurotransmitter release in the brain while protecting against DNA damage. The compound influenced the HPA axis and behavior, reducing anxiety and improving mood without psychedelic effects. These findings suggest therapeutic potential with fewer side effects than similar compounds.
Abstract
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive dis...
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
The International journal on drug policy – August 01, 2024
Summary
A groundbreaking international survey reveals that personal growth, not recreation, is the primary motivation for psychedelic use across global regions. This comparative analysis of 6,379 adults from 85 countries found that psilocybin, LSD, and MDMA are the most commonly used substances. Usage patterns vary by region, with North Americans more likely to microdose and seek therapeutic benefits. Most users prefer legal, quality-controlled sources and practice infrequent, intentional use.
Abstract
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations acro...
Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks.
Acta medica Lituanica – January 01, 2025
Summary
Four people recently hospitalized for consuming *Amanita muscaria* were all discharged in stable condition, revealing a growing trend. This review highlights increased recreational use of these psychoactive mushrooms, driven by compounds like muscimol and its precursor, ibotenic acid. While some explore microdosing, the unregulated nature of *Amanita muscaria* raises public health concerns regarding its known toxicity.
Abstract
The increasing popularity of Amanita muscaria, driven by its hallucinogenic properties, has raised significant public health concerns, particularly...
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
Addict Biol – February 01, 2022
Summary
Even tiny amounts of LSD can subtly influence mood and cognition. Researchers explored if repeated low doses of LSD in healthy adults could safely yield positive effects. Participants received different microdoses or a placebo. Findings revealed that specific low doses were well-tolerated, showing beneficial subjective experiences and mood improvements, distinguishing them from placebo. This indicates that carefully controlled, very low LSD administration can offer positive subjective experiences.
Abstract
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
Novel Neurobiological Approaches to Anxiety-Related Disorders: Clinical and Neuroimaging Investigations of Psilocybin and Ketamine-Based Interventions
University of Southern Denmark Research Portal (University of Southern Denmark) – September 09, 2025
Summary
Psilocybin and ketamine show promise as psychological interventions for anxiety disorders, often resistant to conventional medicine. Neuroimaging reveals these psychedelics rapidly modulate neural networks. Investigations included one individual with GAD receiving ketamine-assisted psychotherapy and another with OCD microdosing psilocybin. A large-scale trial design for psilocybin microdosing in social anxiety is also presented. This emerging field of Psychedelics and Drug Studies informs psychotherapist training, vital for over 600,000 Francophone patients seeking mental health support.
Abstract
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD)...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
Greater subjective effects of a low dose of LSD in participants with depressed mood.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – April 01, 2024
Summary
A low dose of LSD produced stronger positive effects in people with depressive symptoms compared to non-depressed individuals. In this placebo-controlled trial, participants received either a micro-dose of LSD or placebo. Those with higher depression scores reported greater improvements in mood, energy, and emotional well-being. The benefits persisted two days after treatment, suggesting therapeutic potential for low-dose psychedelics in mood enhancement.
Abstract
Recent studies and anecdotal reports suggest that psychedelics can improve mood states, even at low doses. However, few placebo-controlled studies ...
The Rising Use of LSD among Business Managers.
Substance use & misuse – January 01, 2024
Summary
A surprising trend has emerged in corporate America: business managers are increasingly turning to psychedelics, particularly LSD, at higher rates than other workforce segments. Data from 168,920 full-time employees reveals that management-level professionals are embracing these substances, possibly seeking creative and competitive advantages. This upward trend persists across gender lines and appears unrelated to changes in risk perception.
Abstract
Although studies have demonstrated that the use of lysergic acid diethylamide (LSD) is on the rise in the United States, it remains unclear how thi...